Table 4.

Vaccine efficacy against CIN2+ in different geographical regions (Latin America, Asia-Pacific, and Europe).

Study [reference]	Vaccine type∗	Geographical region	Protocols included	Women enrolled	Outcomes assessed	Lesion n/N		VE% (95% CI)
						Vaccine	Control
Perez et al. [31]	Q	Latin America	V501-007; V501-0013; V501-0015; V501-0016; V501-0018	6400	CIN2+ HPV 6/11/16/18 in
					ATP cohort	1/2415	21/2377	95.3 (71.0, 99.9)
					TVC-naïve	3/2671	26/2681	88.5 (62.5, 97.8)
					TVC	45/2718	67/2725	33.1 (1.0, 55.2)
Tay et al. [32]	Q	Asia-Pacific	V501-0013; V501-0015; V501-0016	814	CIN2+ HPV 6/11/16/18 in
					ATP cohort	0/302	5/312	100.0 (−12.4, 100.0)
Majewski et al. [33]	Q	Europe	V501-007; V501-0013; V501-0015; V501-0016	9265	CIN2+ HPV 6/11/16/18 in
					ATP cohort	0/4043	38/4043	100.0 (89.9, 100.0)
					CIN2+ any type in
					TVC-naïve	23/2470	54/2527	56.6 (28.0, 74.6)
Barr et al. [34]	Q	North America	V501-005; V501-007; V501-0013; V501-0015; V501-0016	5996	CIN2+ HPV 16/18 in
					TVC-naïve	0/2100	35/2116	100.0 (89.0, 100.0)
					TVC	19/2313	57/2356	66.4 (42.7, 81.1)
					CIN2+ any type in
					TVC	72/2313	108/2356	33.0 (8.9, 51.0)
de Carvalho et al. [35]	B	Brazil	NCT00689741 HPV001; NCT00120848 HPV007; NCT00518336 HPV023	431	CIN2+ HPV 16/18 in
					TVC	0/219	3/212	100.0 (−129.8, 100.0)
					CIN2+ any type in
					TVC	5/219	8/212	40.6 (−106.0, 84.7)

CIN: cervical intraepithelial neoplasia; ATP: according to protocol; TVC: total vaccine cohort.

^∗Vaccine type Q = quadrivalent; B = bivalent.